Infinity Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Date: December 1, 2010
Pages: 78
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: IB137F32B29EN
Leaflet:

Download PDF Leaflet

Infinity Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Infinity Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Infinity Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Infinity Pharmaceuticals, Inc. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Infinity Pharmaceuticals, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Infinity Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Infinity Pharmaceuticals, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Infinity Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Infinity Pharmaceuticals, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Infinity Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Infinity Pharmaceuticals, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Infinity Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Infinity Pharmaceuticals, Inc. Snapshot
Infinity Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Infinity Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Infinity Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Infinity Pharmaceuticals, Inc. – Pipeline Products Glance
Infinity Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Infinity Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Infinity Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Infinity Pharmaceuticals, Inc. – Drug Profiles
IPI-504
  Product Description
  Mechanism of Action
  R&D Progress
IPI-504
  Product Description
  Mechanism of Action
  R&D Progress
IPI-504 + Herceptin
  Product Description
  Mechanism of Action
  R&D Progress
IPI-926 + Gemzar
  Product Description
  Mechanism of Action
  R&D Progress
IPI-493
  Product Description
  Mechanism of Action
  R&D Progress
IPI-504
  Product Description
  Mechanism of Action
  R&D Progress
IPI-504 + Taxotere
  Product Description
  Mechanism of Action
  R&D Progress
IPI-926
  Product Description
  Mechanism of Action
  R&D Progress
IPI-940
  Product Description
  Mechanism of Action
  R&D Progress
IPI-145
  Product Description
  Mechanism of Action
  R&D Progress
PI3K delta/gamma Inhibitor
  Product Description
  Mechanism of Action
  R&D Progress
Infinity Pharmaceuticals, Inc. – Pipeline Analysis
Infinity Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Infinity Pharmaceuticals, Inc. Pipeline Products By Target
Infinity Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Infinity Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Infinity Pharmaceuticals, Inc. – Recent Pipeline Updates
Infinity Pharmaceuticals, Inc. – Company Statement
Infinity Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 16, 2010: Infinity Conducts Phase Ib/II Clinical Trial Of IPI-926 In Pancreatic Cancer
Nov 15, 2010: Infinity Conducting IPI-926 Clinical Trial In Patients With Pancreatic Cancer In Dallas
Oct 14, 2010: Infinity Reports Publication Of Phase II Study Results Of IPI-504 In Patients With Non-Small Cell Lung Cancer In Journal Of Clinical Oncology
Oct 11, 2010: Infinity Announces Promising Phase I Data Of IPI-926 In Advanced Or Metastatic Solid Tumors
Jun 24, 2010: Infinity Initiates Phase I Clinical Trial Of IPI-493 In Patients With Advanced Hematologic Malignancies
Apr 21, 2010: Infinity Initiates Clinical Trial Of IPI-926 In Pancreatic Cancer
Apr 21, 2010: Infinity Reports New Preclinical Data Of IPI-926 In Pancreatic Cancer At AACR
Apr 21, 2010: Infinity Reports New Preclinical Data Of IPI-926 In Pancreatic Cancer At AACR
Apr 21, 2010: Infinity Reports New Preclinical Data Of IPI-926 In Pancreatic Cancer At AACR
Mar 12, 2010: Infinity's Hedgehog Pathway Inhibitor Program To Be Highlighted At Upcoming Conferences
Financial Deals Landscape
Infinity Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Infinity Pharmaceuticals, Inc. Detailed Deal Summary
Asset Purchase
Infinity Pharmaceuticals Re-Aquires Rights Of Hsp90 Program From MedImmune
Acquisition
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity
Infinity Pharmaceuticals Acquires Biofrontera Discovery From Biofrontera
Equity Offering
Infinity Pharmaceuticals Completes Second Equity Financing Of $30 Million
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Mundipharma And Purdue Pharmaceutical
MedImmune Enters Into Agreement With Infinity Pharmaceuticals
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Novartis
Discovery Partners Enters Into Co-Development Agreement With Mitsubishi Pharma
Discovery Partners Enters Into Collaboration With Ono Pharmaceutical
Biovitrum Enters Into Research Agreement With Discovery Partners
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Novartis
Discovery Partners International Enters Into An Agreement With Vertex
Discovery Partners Enters Into Drug Discovery Collaboration With Chroma Therapeutics
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Pfizer
Discovery Partners International Enters Into An Agreement With Pfizer
Discovery Partners International Enters Into A Research Agreement With Celltech
Discovery Partners Terminates Co- Development Agreement With Pfizer
Licensing Agreements
Infinity Pharmaceuticals Enters Into Licensing Agreement With Amgen
Infinity Pharmaceuticals Enters Into Agreement With Johnson & Johnson
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 78

LIST OF TABLES

Infinity Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Infinity Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Infinity Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Infinity Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
Infinity Pharmaceuticals, Inc. – Phase III, 2010
Infinity Pharmaceuticals, Inc. - Phase II, 2010
Infinity Pharmaceuticals, Inc. - Phase I, 2010
Infinity Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2010
Infinity Pharmaceuticals, Inc. - Pipeline By Target, 2010
Infinity Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010
Infinity Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2010
Infinity Pharmaceuticals, Inc. – Recent Pipeline Updates, 2010
Infinity Pharmaceuticals, Inc., Deals Summary, 2004 to 2010
Infinity Pharmaceuticals Re-Aquires Rights Of Hsp90 Program From MedImmune
Infinity Pharmaceuticals Reacquires Rights of Hedgehog Pathway Program
Infinity Pharmaceuticals Sells Its Discovery Systems Business To Nexus Biosystems
Galapagos Acquires Discovery Partners, ChemRx, Xenometrix And Discovery Partners International From Infinity
Infinity Pharmaceuticals Acquires Biofrontera Discovery From Biofrontera
Infinity Pharmaceuticals Completes Second Equity Financing Of $30 Million
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Mundipharma And Purdue Pharmaceutical
MedImmune Enters Into Agreement With Infinity Pharmaceuticals
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Novartis
Discovery Partners Enters Into Co-Development Agreement With Mitsubishi Pharma
Discovery Partners Enters Into Collaboration With Ono Pharmaceutical
Biovitrum Enters Into Research Agreement With Discovery Partners
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Novartis
Discovery Partners International Enters Into An Agreement With Vertex
Discovery Partners Enters Into Drug Discovery Collaboration With Chroma Therapeutics
Infinity Pharmaceuticals Enters Into Collaboration Agreement With Pfizer
Discovery Partners International Enters Into An Agreement With Pfizer
Discovery Partners International Enters Into A Research Agreement With Celltech
Discovery Partners Terminates Co- Development Agreement With Pfizer
Infinity Pharmaceuticals Enters Into Licensing Agreement With Amgen
Infinity Pharmaceuticals Enters Into Agreement With Johnson & Johnson 76

LIST OF FIGURES

Infinity Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2010
Infinity Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2010
Infinity Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2010
Infinity Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, 2010
Infinity Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2010
Infinity Pharmaceuticals, Inc. - Pipeline By Target, 2010
Infinity Pharmaceuticals, Inc. – Pipeline By Route of Administration, 2010 36

Ask Your Question

Infinity Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: